Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Tykerb Combo Gains Accelerated Approval | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Tykerb Combo Gains Accelerated Approval

GlaxoSmithKline received accelerated approval from the FDA for a new combination regimen using Tykerb (lapatinib) as a first-line, oral treatment for women with metastatic breast cancer.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline received accelerated approval from the FDA for a new combination regimen using Tykerb (lapatinib) as a first-line, oral treatment for women with metastatic breast cancer. Tykerb is now indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated.

“This combination of Tykerb plus Femara is an example of advancing science and improving patient care. This regimen attacks two specific receptors that drive cancer growth,” said Paolo Paoletti, senior vice president, GSK Oncology R&D.“Women battling this disease now have the opportunity to delay the use of traditional cytotoxic-chemotherapy, which is an exciting possibility for them.”

Tykerb was already indicated in combination with Xeloda (capecitabine) for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters